ANTITHROMBOTIC THERAPY AFTER LEFT ATRIAL APPENDAGE OCCLUSION: DOUBLE ANTIPLATELET THERAPY VS. APIXABAN - ADALA

HOSPITAL CLÍNIC BARCELONA0 个研究点目标入组 160 人开始时间: 2018年8月10日最近更新: 2019年1月7日

适应症

试验速览

暂无简介。

•Age> 18 years
•NVAF (paroxysmal, persistent or permanent)
•CHADS2 score =1 or CHA2DS2-VASc score =2
•* Adequate anatomy for LAA closure and contraindication for OAC (absolute or relative).
•Able to give informed consent and to be followed-up (phone and clinical visit)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 24
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 136

•Patients with mechanical prostheses, evidence of thrombus, complex aortic atheroma or symptomatic carotid disease
•Contraindication for TEE studies
•Platelets <40000
•Absolute contraindication to Apixaban for 3 months (severe renal failure with Cl. creat <15 ml / h or severe liver disease Child B or C) or allergy to the drug.
•Contraindication to any form of anticoagulation or antiplatelet therapy.
•Patients with a history of drug or alcohol abuse, or psychosocial reasons that preclude the follow-up of the patient.
•Women of childbearing potential (WOCB)

发起方

HOSPITAL CLÍNIC BARCELONA